IBIO INC (IBIO)

Company Profile

Ibio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Bryan, Texas and currently employs 26 full-time employees. The company went IPO on 2008-08-18. iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. The company is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, CCR8 and PD-1 Agonist. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Company Info

IBIO INC

8800 HSC Pkwy

Bryan TEXAS 77807

P: 19794460027

CEO: Thomas F. Isett

Employees: 26

Website: https://www.ibioinc.com/